TrumpRx Secret Deals? Lawmakers Demand Clarity as Pharma Execs Say They Must 'Take Their Word'

A wave of questions surrounds the transparency and future impact of President Donald Trump's recent efforts to lower drug prices. As the administration pushes to make medicines more affordable, lawmakers demand clarity on the details behind Trump's secret negotiations with big pharmaceutical firms.

Lawmakers question the transparency

During a House Energy and Commerce Committee hearing on Wednesday, members pressed industry leaders for details. Concerns boiled over about what exactly was agreed upon, who benefits, and whether these deals will stick.

Rachel Sachs, a law professor at Washington University, voiced her doubts.

'We don't know basic things like which drugs are included, what the agreed-upon prices are, and to whom they will be available?' Sachs posed the question.

'And how does the government have any ability to detect and enforce violations of these agreements?' she pressed on.

PhRMA CEO Lori Reilly responded, saying they'd just 'have to take their word for it' that the deals benefit consumers. Her tone drew sharp criticism from New Jersey Rep. Frank Pallone, the committee's ranking member.

'It's absurd for me to take the word for it. I mean, that's not what we do,' Pallone said. 'We don't take the word for anybody. We question, we do oversight, we look into it.'

The launch of TrumpRx and its promises

Last week, the Trump administration unveiled TrumpRx.com, a new website promising Americans access to lower-cost prescriptions. It offers coupons for 43 drugs, including fertility treatments and weight-loss medications.

The aim: make medications cheaper, especially for uninsured Americans.

Trump announced, 'Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers throughout a new website.'

The website's creation was a lengthy process.

Over a year, officials met with at least 16 pharmaceutical companies to negotiate deals that would prevent U.S. consumers from paying more than those in other countries. The effort was part of the administration's broader push to reshape drug pricing.

Cost savings and consumer impact

Some drugs are already showing promise. The website features discounts on fertility and weight-loss medications that could save consumers hundreds of dollars. Yet, experts warn that for most prescriptions, insurance remains the cheaper option.

Dr Ben Rome, a health policy researcher at Boston's Brigham and Women's Hospital, told NPR, 'This is a website that has undergone a lot of hype, but it's not clear exactly how much it's going to help those people who use prescription drugs.'

'And for the vast majority of people, it's going to continue to be less expensive for patients to purchase their medicines using their insurance than it is to pay cash prices for the medicines, even if those cash prices are highly discounted below the manufacturer prices,' he continued.

Industry moves and smaller companies on the sidelines

While 16 large drug companies signed deals with the Trump administration, many others are watching closely. Some are seeking their own arrangements to avoid upcoming Medicare price controls. Industry sources reveal efforts to negotiate directly with officials at the White House and the Centers for Medicare & Medicaid Services.

'Companies have begun reaching out to contacts at the White House and the CMS to try to create their own deals,' said one industry insider. They did not reveal which companies are involved.

Kush Desai, spokesperson for the White House confirmed the administration's goal through an email to Reuters.

'The Trump administration of course wants to negotiate deals that meaningfully lower drug prices for American patients with every pharmaceutical company,' he wrote.

Concerns swirl about new Medicare pilot programmes. These initiatives could set drug prices in large parts of the country, requiring rebates for medicines paid for by Medicare if US prices are higher than those abroad.

The divide among drug companies

Big players like Pfizer and Eli Lilly have already struck deals. But many others remain uncontacted.

Bayer's Stefan Oelrich expects smaller firms will be given opportunities to negotiate similar deals. 'Otherwise that would be very odd, that only because you have size that you would get different treatment,' he said.

Smaller firms, feeling squeezed, have formed a new lobby group: the Midsized Biotech Alliance of America. Its members include Alkermes, BioMarin, Incyte, and Alnylam. They're concerned about being cut out of the benefits of the deals and the potential for future government-imposed price controls.

Sanofi's CEO Paul Hudson voiced fears at the JP Morgan Healthcare Conference in San Francisco.

'There's a large group of companies that don't have a deal and what are they left with?' he asked.

'The nature of the deals, which some companies have said exempt them from future government price-setting initiatives, could make it hard for the government to offer similar options to smaller companies,' he added.

US consumers pay by far the highest prices for prescriptions globally. Studies show Americans often pay nearly three times more than residents of other developed nations. The recent moves aim to change that, but critics say the real impact remains uncertain.